
Sign up to save your podcasts
Or


In this episode, Fred Hutch cancer prevention researcher Dr. Jonathan Bricker talks about QuitQuest, a new digital app designed to help teens stop vaping. Vaping is particularly risky for teens not just because of the cancer-causing chemicals that are inhaled but the impact of nicotine on adolescent brain development and the increased likelihood of addiction – not just to nicotine but other drugs.
Key Topics:
Many teens are unaware that vapes contain nicotine. And even vaping products labeled "nicotine-free" may contain nicotine, which teens are also not aware of.
Nicotine salts make the vapes both strong and smooth, producing a very powerful addiction.
Many vapes come in "fruity" or "candy" flavoring which make them more attractive to teens. They "feel" safe, but they are not. They contain aerosols that travel deep into the lungs – nickel, lead and other chemicals that can cause cancer.
Dr. Bricker worked with a Community Advisory Board comprised of parents, teens who vaped and others advocates to create an effective app that teens will want to use.
This is the latest in a series digitals apps that Dr. Bricker has created to help people stop unhealthy behaviors such as smoking, vaping or overeating.
Most of his approaches use ACT (Acceptance and Commitment Therapy) coupled with a digital approach such as a smartphone app.
QuitQuest uses a gaming design, where teens battle "monsters" – the cravings they're trying to beat – and eventually learn how to live with the cravings and get past them.
The study will launch in 2027, the latest incarnation of Fred Hutch's longstanding commitment to help reduce the cancer burden. "Tobacco control research is in Fred Hutch's DNA," said Dr. Bricker.
Fred Hutch scientists have a new theory of cancer. They argue that we should trace cancer's origins to DNA packaging and gene transcription, rather than DNA mutations. This could upend our understanding of cancer and also have big implications for improving chemotherapy.
Dr. Cassandra Simonich talks with John Higgins in the lab about respiratory syncytial virus, or RSV, the leading cause of infant hospitalization in the United States. She discusses a study recently published in Nature that she co-authored with Dr. Jesse Bloom, an evolutionary biologist at Fred Hutch Cancer Center. The study confirms that current prevention therapies are safe and effective. Their innovative methods enable real-time surveillance of how RSV is evolving and provides a roadmap to weak links in RSV and potentially in other viruses that researchers can use to make better therapies.
Key Takeaways
Dr. Tom Purcell, chief medical officer at Fred Hutch Cancer Center, discusses what the future of cancer care may hold in terms of monitoring recurrence and promoting health, as well as how Fred Hutch's streamlined cancer survivorship models help support patients.
Key takeaways:
Dedicated providers oversee the long-term care of patients who are no longer in active cancer treatment.
The survivorship program focuses on improving overall quality of life by addressing the myriad personal and medical aspects of life after a cancer diagnosis
Dr. Purcell wraps up a six-part podcast series on cancer survivorship. See fredhutch.org/news for other episodes
Dr. Jeremy Hollis talks with John Higgins about the two molecular mysteries that he solved on the way to earning his doctorate degree at Fred Hutch Cancer Center. His solution to the first case provided insight into the evolution of the human immune system and opened new possibilities for drugs and therapies when cell signaling goes awry. His solution to the second showed researchers a new way to trace the evolution of life's most ancient molecular machines when genomic sequences become unrecognizable using standard methods.
Takeaways:
In this episode of Bench to Bedside and Beyond, Fred Hutch's Diane Mapes talks with clinical researcher and breast cancer oncologist Dr. Rachel Yung, co-director of the Breast and Ovarian Cancer Prevention Clinic at Fred Hutch, about hereditary cancer risk, genetic testing for hereditary cancers and ways to reduce your risk if you are told you have a pathogenic variant.
Key takeaways:
Dr. Matthew Ross talks with John Higgins about the problems he has solved for Fred Hutch researchers using a donated 3D printer. Ross, the communications liaison for Fred Hutch Cancer Center's Basic Sciences Division, used the printer to fabricate small parts, make customized tools and create scale models of life's smallest molecular machines. Scientists and aspiring scientists can hold these models in their hands to see — and feel — their shape to infer their function.
Key takeaways
Dr. Matthew Ross uses a donated 3D printer to make spare parts, customized tools and models of life's smallest molecular machines for teaching and learning.
3D printing helps the Basic Sciences Division maintain older, specialized equipment, saving money that can be reinvested in research.
Scale models of proteins that researchers can hold in their hands provide tangible information about their structure, making the visual science of structural biology more accessible to someone with visual impairments.
In this episode of Bench to Bedside and Beyond, Diane Mapes talks with Fred Hutch Cancer Center and UW Medicine clinical researcher and gynecologic oncologist Dr. Elizabeth Swisher about research that may refine how scientists understand and treat tubo-ovarian cancer — and potentially help guide targeted treatment for some people with triple-negative breast cancer.
Swisher explains why many cancers long called ovarian cancer begin in the fallopian tubes, why "tubo-ovarian cancer" is a more accurate term and how researchers are studying tumors' current biological vulnerabilities to better match patients with treatment options. The conversation also explores HRDefine, an investigational assay designed to identify the current causes of homologous recombination deficiency, or HRD, a tumor weakness that can make some cancers responsive to PARP inhibitors.
Key takeaways
Many cancers commonly called ovarian cancer begin in the fallopian tubes. Using the term tubo-ovarian cancer more accurately reflects where these cancers often originate and may inform future prevention and early-detection research.
Homologous recombination deficiency, or HRD, is a weakness in how some tumor cells repair damaged DNA. That weakness can make certain tumors more responsive to PARP inhibitors.
Swisher and colleagues developed HRDefine, an investigational assay designed to identify the current cause of HRD. It can examine BRCA1/2 and other gene changes, as well as methylation changes that can affect gene activity.
Unlike older measures of HRD, which may continue to show a past vulnerability after a tumor has become resistant to treatment, HRDefine is designed to assess the tumor's current biology.
The assay may help identify which patients are most likely to benefit from PARP inhibitors in tubo-ovarian cancer and, potentially, triple-negative breast cancer. It is still being validated in hundreds of samples before any broader clinical or commercial use.
This work reflects a broader goal of precision oncology: matching treatment decisions to a tumor's biological features, not solely to the organ where the cancer began or to inherited genetic risk.
John Higgins interviews Dr. Rashmi Mishra, a postdoctoral research fellow in the Hsieh Lab at Fred Hutch Cancer Center, about how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. In a recent study, she and her colleagues found potential ways to reverse that trick, forcing tumor cells to shapeshift back into the more treatable form. Their discovery opens a new line of attack against aggressive prostate cancer, as well as breast cancer and possibly other cancers.
Key Takeaways:
From the publisher's feed